odanacatib and Kidney-Neoplasms

odanacatib has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for odanacatib and Kidney-Neoplasms

ArticleYear
Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
    Redox biology, 2020, Volume: 30

    Cathepsin K (Cat K) is expressed in cancer cells, but the effect of Cat K on apoptosis is still elusive. Here, we showed that inhibition of Cat K sensitized the human carcinoma cells to anti-cancer drug through up-regulation of Bim. Inhibition of Cat K increased USP27x expression, and knock down of USP27x markedly blocked Cat K-induced up-regulation of Bim expression. Furthermore, inhibition of Cat K induced proteasome-dependent degradation of regulatory associated protein of mammalian target of rapamycin (Raptor). Down-regulation of Raptor expression increased mitochondrial ROS production, and mitochondria specific superoxide scavengers prevented USP27x-mediated stabilization of Bim by inhibition of Cat K. Moreover, combined treatment with Cat K inhibitor (odanacatib) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reduced tumor growth and induced cell death in a xenograft model. Our results demonstrate that Cat K inhibition enhances anti-cancer drug sensitivity through USP27x-mediated the up-regulation of Bim via the down-regulation of Raptor.

    Topics: Animals; Antineoplastic Agents; Bcl-2-Like Protein 11; Biphenyl Compounds; Cathepsin K; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Kidney Neoplasms; Male; Mice; Mitochondria; Protein Stability; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand; Ubiquitin-Specific Proteases; Xenograft Model Antitumor Assays

2020